Standard Biotools (NYSE: LAB) — Perfil da empresa, notícias e dados financeiros
Standard Biotools develops tools for life sciences, focusing on genomic and cell biology research to accelerate scientific discovery.
Standard Biotools
Standard Biotools (NASDAQ:LAB) is a company engaged in the design, development, and commercialization of tools for the life sciences community. Its operations span across the development of innovative technologies and systems that enable genomic and cell biology research, aiming to contribute to breakthroughs in scientific understanding and medical research. Standard Biotools focuses on delivering high-quality solutions that meet the evolving needs of researchers and scientists in the biotechnological field. Their projects range from developing sophisticated instruments and consumables to providing comprehensive analytical software solutions. The company's objective is to accelerate scientific discovery by offering products that enhance the efficiency and effectiveness of laboratory research.
Resumo
Operações
Produtos e/ou serviços de Standard Biotools
- Fluidigm - An integrated fluidic circuit technology designed for various genomic analysis applications, including genotyping, PCR, and next-generation sequencing.
- C1 Single-Cell Auto Prep System - Enables automated preparation of single cells for genomic analysis, enhancing precision and efficiency in research.
- Juno System - A microfluidic-based platform for genotyping and targeted DNA sequencing, offering high throughput and versatility in sample processing.
- Biomark HD System - A high-throughput PCR system enabling sensitive and accurate gene expression analysis, genotyping and digital PCR.
- Helios Mass Cytometer - Employs CyTOF technology for high-dimensional single-cell analysis, enabling detailed cell profiling in immunology and cancer research.
- Access Array System - Facilitates high-throughput targeted resequencing, enriching multiple genomic targets in a single sequencing run for cost-effective variant detection.
equipe executiva do Standard Biotools
- Michael EgholmPresident, CEO & Director
- Hanjoon KimChief Financial Officer
- Sean MackaySenior VP & Chief Business Officer
- Jonathan MickelsenVP & Chief Accounting Officer
- John GrazianoVice President of Investor Relations
- Elizabeth R. JensenChief Human Resources Officer
- Anders DavasSenior Vice President of Global Operations
- Mike MusgnugSenior VP & Chief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela Standard Biotools, em USD.
- Cap. de mercado
- 243,5 mi
- Receita (TTM)
- 84,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- 100.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 85,3 mi | -93,3 mi | -74,9 mi | |
| 174,4 mi | -175,2 mi | -138,9 mi | |
| 106,3 mi | -76,6 mi | -74,7 mi | |
| 97,9 mi | -116,2 mi | -190,1 mi |